MX2020011665A - Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. - Google Patents

Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica.

Info

Publication number
MX2020011665A
MX2020011665A MX2020011665A MX2020011665A MX2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
addition salt
crystal form
receptor agonist
crystalline form
Prior art date
Application number
MX2020011665A
Other languages
English (en)
Spanish (es)
Inventor
Wei Zheng
Wubin Pan
Jiawang Guo
Original Assignee
Suzhou Connect Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Connect Biopharmaceuticals Ltd filed Critical Suzhou Connect Biopharmaceuticals Ltd
Publication of MX2020011665A publication Critical patent/MX2020011665A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020011665A 2018-05-04 2018-05-04 Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. MX2020011665A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Publications (1)

Publication Number Publication Date
MX2020011665A true MX2020011665A (es) 2021-01-20

Family

ID=68387039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011665A MX2020011665A (es) 2018-05-04 2018-05-04 Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica.

Country Status (13)

Country Link
US (3) US11512078B2 (enExample)
EP (2) EP4353719B1 (enExample)
JP (3) JP7275253B2 (enExample)
KR (2) KR102672632B1 (enExample)
AU (1) AU2018421487B2 (enExample)
CA (1) CA3099196A1 (enExample)
ES (1) ES2978392T3 (enExample)
IL (3) IL278464B2 (enExample)
MX (1) MX2020011665A (enExample)
NZ (1) NZ770323A (enExample)
SG (1) SG11202010969UA (enExample)
WO (1) WO2019210511A1 (enExample)
ZA (1) ZA202007347B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7275253B2 (ja) * 2018-05-04 2023-05-17 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
CA3201000A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549640A4 (en) * 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
CN103450171B (zh) * 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
CN105315266B (zh) 2014-08-01 2019-10-01 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
CN115772166B (zh) * 2017-01-11 2025-01-03 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
JP7275253B2 (ja) * 2018-05-04 2023-05-17 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Also Published As

Publication number Publication date
US20250320200A1 (en) 2025-10-16
US12202822B2 (en) 2025-01-21
ES2978392T3 (es) 2024-09-11
IL312512A (en) 2024-07-01
IL278464A (enExample) 2021-03-01
IL312512B1 (en) 2025-11-01
CA3099196A1 (en) 2019-11-07
IL278464B1 (en) 2024-06-01
AU2018421487A1 (en) 2020-12-17
KR20240094023A (ko) 2024-06-24
AU2018421487B2 (en) 2024-09-12
EP4353719A1 (en) 2024-04-17
EP3792258A4 (en) 2021-10-06
JP7651198B2 (ja) 2025-03-26
JP2025074350A (ja) 2025-05-13
IL323665A (en) 2025-11-01
US11512078B2 (en) 2022-11-29
BR112020022429A2 (pt) 2021-02-09
EP4353719B1 (en) 2025-12-24
US20230050777A1 (en) 2023-02-16
JP7275253B2 (ja) 2023-05-17
US20210230152A1 (en) 2021-07-29
WO2019210511A1 (zh) 2019-11-07
IL312512B2 (en) 2026-03-01
NZ770323A (en) 2025-12-19
JP2023062091A (ja) 2023-05-02
EP3792258B1 (en) 2024-02-07
SG11202010969UA (en) 2020-12-30
KR102672632B1 (ko) 2024-06-07
EP3792258A1 (en) 2021-03-17
JP2021532165A (ja) 2021-11-25
KR20210019999A (ko) 2021-02-23
IL278464B2 (en) 2024-10-01
ZA202007347B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
BR112014012815A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
SV2009002857A (es) Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
ECSP19044591A (es) Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina
CL2020000601A1 (es) Composición farmacéutica.
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
PH12019502767A1 (en) Oral pharmaceutical formulations of remogliflozin
NZ770323A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
RU2013147196A (ru) Агонист рецептора 5-нт4 в качестве прокинетического агента